Psyence Group Enters into Agreements with its NASDAQ-Listed Associate, Psyence Biomedical, to settle outstanding obligations Dec 6, 2024 11:06AM
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Recruitment of Second Clinical Trial Site for Ongoing Phase IIb Clinical Trial of Nature-Derived Psilocybin for Adjustment D Oct 25, 2024 09:42AM
Psyence Group Enters into Debt-for-Equity Swap Agreement with its NASDAQ-Listed Associate, Psyence Biomedical Oct 14, 2024 10:43AM
Psyence Group Enters into Agreement to Dispose of Stake in PsyLabs Sep 20, 2024 11:20AM
Psyence Group's NASDAQ-Listed Associate, Psyence Biomed Issues Shareholder Update Recapping Recent Progress and Previewing Key Upcoming Data Milestones Sep 18, 2024 09:30AM


Sep 16, 2024 09:31AM Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Initiation of First Trial Site in Australia for its Phase IIb Study of Nature Derived Psilocybin as a Potential Treatment fo
Jul 26, 2024 09:30AM Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, Announces Export of Nature-Derived Psilocybin to Australia and Provides Update on Upcoming Phase IIb Trial
Apr 16, 2024 11:01AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical Partners with Fluence and iNGENū CRO to Train Research Therapists for Phase IIb Psilocybin Trial
Mar 26, 2024 11:06AM Psyence Group Announces the Closing of the Previously Announced Strategic Restructuring of Its Non-Clinical Business
Mar 12, 2024 11:15AM Psyence Group's NASDAQ Listed Associate, Psyence Biomedical, Receives Human Research Ethics Committee (HREC) Approval to Initiate Phase IIb Study  
Mar 11, 2024 07:00AM Psyence Group Provides Corporate Update Following Successful Spac Spin Out of Therapeutic Division
Jan 26, 2024 05:20AM Psyence Biomedical (PSYG) Approved to List on Nasdaq following Completion of Merger with Newcourt Acquisition Corp
Jan 25, 2024 06:03PM Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Jan 25, 2024 05:17PM Psyence Biomedical Ltd. Approved to List on Nasdaq following Completion of Business Combination Agreement with Newcourt Acquisition Corp
Jan 16, 2024 07:54AM Psyence Group Inc Subsidiary Psyence Biomedical Ltd. announces signing of definitive agreement for a convertible note in connection with planned business combination
Aug 2, 2023 10:34AM Psyence Group Announces SEC Registration Filing with NASDAQ SPAC, Newcourt, and Signing of Amended and Restated Business Combination Agreement
Mar 23, 2023 07:00AM Psyence Group Announces Cantheon Capital Private Placement
Mar 21, 2023 07:00AM Psyence Partners with iNGENū for Palliative Care Clinical Trial in Australia
Jan 24, 2023 07:00AM Psyence and Eden Labs Announce Extraction and Product Development Collaboration
Jan 9, 2023 05:47PM Psyence Announces Business Combination between Wholly Owned Subsidiary Psyence Biomed Corp. and Nasdaq listed Newcourt Acquisition Corp
Jan 8, 2023 07:00PM Psyence Signs Letter of Intent with Australian CRO iNGENū
Dec 15, 2022 08:47AM Psyence and Filament Health Announce Worldwide Licensing Agreement of Psilocybin Capsule for Palliative Care
Sep 22, 2022 07:00AM Psyence Group Completes Export of Psilocybin Mushrooms to Canada
Aug 10, 2022 08:22AM The Flowr Corporation Announces Leadership Transition and Changes to Board of Directors
Apr 19, 2022 07:00AM Psyence and Filament Health Enter Into Exclusive Licensing Agreement for Natural Psilocybin Products